

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cardiovascular disease				
Arterial thrombosis	Purinergic receptor P2X ligand-gated ion channel 7 (P2RX7; P2X7)	<p>Mouse studies suggest inhibiting P2RX7 could help prevent arterial thrombosis. In mice, knockout of <i>P2rx7</i> prevented injury-induced arterial thrombosis compared with expression of <i>P2rx7</i>. Next steps include evaluating a P2RX7 antagonist in animal models.</p> <p>EVT 401, an oral small molecule P2RX7 receptor antagonist from Evotec AG, is in Phase I testing for rheumatoid arthritis (RA).</p> <p>GSK1482160, a purinergic ATP receptor antagonist targeting P2RX7 from GlaxoSmithKline plc, is in Phase I testing to treat pain.</p> <p>Affectis Pharmaceuticals AG's AFC-5128, a P2RX7 receptor antagonist, is in preclinical development to treat pain.</p> <p>SciBX 4(25); doi:10.1038/scibx.2011.709 Published online June 23, 2011</p>	Work unpatented; licensing status not applicable	<p>Furlan-Freguia, C. <i>et al. J. Clin. Invest.</i>; published online June 13, 2011; doi:10.1172/JCI46129</p> <p>Contact: Wolfram Ruf, The Scripps Research Institute, La Jolla, Calif. e-mail: ruf@scripps.edu</p>